HER2 genomic amplification in circulating tumor DNA and estrogen receptor positivity predict primary resistance to trastuzumab emtansine (T-DM1) in patients with HER2-positive metastatic breast cancer.
about
HER2 genomic amplification in circulating tumor DNA and estrogen receptor positivity predict primary resistance to trastuzumab emtansine (T-DM1) in patients with HER2-positive metastatic breast cancer.
description
2018 nî lūn-bûn
@nan
2018年の論文
@ja
2018年学术文章
@wuu
2018年学术文章
@zh
2018年学术文章
@zh-cn
2018年学术文章
@zh-hans
2018年学术文章
@zh-my
2018年学术文章
@zh-sg
2018年學術文章
@yue
2018年學術文章
@zh-hant
name
HER2 genomic amplification in ...... tive metastatic breast cancer.
@en
HER2 genomic amplification in ...... tance to trastuzumab emtansine
@nl
type
label
HER2 genomic amplification in ...... tive metastatic breast cancer.
@en
HER2 genomic amplification in ...... tance to trastuzumab emtansine
@nl
prefLabel
HER2 genomic amplification in ...... tive metastatic breast cancer.
@en
HER2 genomic amplification in ...... tance to trastuzumab emtansine
@nl
P2093
P2860
P1433
P1476
HER2 genomic amplification in ...... tive metastatic breast cancer.
@en
P2093
Hitomi Sakai
Junji Tsurutani
Kazuhiko Nakagawa
Kazuko Sakai
Kazuto Nishio
Tsutomu Iwasa
Yoshifumi Komoike
P2860
P2888
P356
10.1007/S12282-018-0861-9
P577
2018-04-26T00:00:00Z